Clinical trials: All Comers
Arterial Occlusive Diseases, Atherosclerosis
A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries
The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions…
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Vascular Diseases, Arteriosclerosis
- Trial name
- REGAL (NCT03037411)
- Testing
- Peripheral stenting
- Where
- 23 sites in Austria, Belgium and 3 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
Aortic Stenosis
TAVR Without Predilatation
The procedure is performed via transfemoral or transcaprotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon…
- Trial name
- TAVIWOP (NCT04350658)
- Testing
- Transcatheter aortic valve implantation required for symptomatic aortic stenosis
- Where
- France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Montpellier
Coronary Artery Disease, Angina Pectoris
DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity
Rationale: The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity but there are further demands on DES performance.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Unstable Angina Pectoris, Acute Coronary Syndrome
- Trial name
- DUTCHPEERS (NCT02175706)
- Testing
- Resolute Integrity®, Promus Element®
- Where
- 4 sites in Netherlands
- Volunteers
- 1,811 people
- Sponsor
- Thorax Centrum Twente
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III All-comers Orsiro Safety and Performance Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-III (NCT01553526)
- Where
- 43 sites in Austria, Chile and 11 more
- Volunteers
- 1,356 people
- Sponsor
- Biotronik AG
All Comers
A-EYE: A Mixed Quantitative and Qualitative Study to Develop and Evaluate the Application of Artificial Intelligence (AI) Methods Using Retinal Imaging for the Identification of Adverse Retinal Changes Associated With Cancer Therapies.
This is a data collection study involving the gathering of clinical data and OCT (optical coherence tomography) scans from 350 patients.
- Trial name
- A-EYE (NCT04901468)
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- University of Manchester
Coronary Artery Disease
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent…
- Trial name
- NOVA (NCT07566091)
- Testing
- Sirolimus-Ascorbic Acid Eluting Stent, Everolimus-Eluting Stent
- Where
- South Korea
- Volunteers
- 2,034 people
- Sponsor
- Jung-min Ahn
Coronary Heart Disease, Angioplasty, Balloon
The Clinical Efficacy and Safety of Drug-coated Balloon
Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty procedurally, but there is an anti-proliferative medication paclitaxel coated on the balloon.
- Trial name
- NCT05133921
- Where
- China
- Volunteers
- 2,487 people
- Sponsor
- Xijing Hospital
Calcific Coronary Arteriosclerosis
Prospective Registry on Intravascular Lithotripsy
multicenter, international, all-comers registry aims to provide insights in the current application of IVL technology in patients with calcified coronary lesions undergoing PCI using IVL technology.
- Trial name
- BENELUX-IVL (NCT06577038)
- Testing
- PCI with use of IVL
- Where
- 8 sites in Belgium, Greece and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Leiden University Medical Center
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Canada Satellite Registry
For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedural success.
- Trial name
- NCT01880242
- Where
- 2 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Biotronik Canada Inc
Coronary Artery Disease, Myocardial Ischemia
Genoss DES Prospective Multicenter Registry
This registry is a clinical post-market evaluation of the Genoss DES in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT03045913
- Testing
- Genoss DES
- Where
- 17 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Young Jin Youn, MD, PhD
Consecutive Subjects Who Are Suitable for a Coronary, Angioplasty of de Novo Lesion(s) in Native Coronary
CRE8 in All Comers Patients
The purpose of the study is to evaluate clinical performances of Cre8 in all comer population in Subjects over 18 years old who are undergoing a clinically indicated coronary angiogram and angioplasty on de-novo lesion located in…
- Conditions
- Consecutive Subjects Who Are Suitable for a Coronary, Angioplasty of de Novo Lesion(s) in Native Coronary, Arteries Should be Screened for Eligibility., A Total Number of 200 Patients Fulfilling the Selection
- Trial name
- NCT01687075
- Testing
- CR8 a drug eluting coronary stent
- Where
- Israel
- Volunteers
- 215 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Angioplasty, Peripheral Arterial Disease
European All-comers' Multicentric Prospective REGISTRY on LUMINOR© Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.
The objective of this all-comers registry is to explore the safety, efficacy, and cost-efficiency of the LUMINOR© DEB in de-novo and restenotic-FP lesions.
- Conditions
- Angioplasty, Peripheral Arterial Disease, Drug-eluting Balloon, Femoral Artery
- Trial name
- LUMIFOLLOW (NCT04743180)
- Testing
- LUMINOR© Paclitaxel eluting balloon
- Where
- 15 sites in France
- Volunteers
- 500 people
- Sponsor
- iVascular S.L.U.
Chinese Patients Treated With Agent DCB
An "All-Comers" Study of the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter Used in Real-World Clinical Practice in Chinese Patients
To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
- Trial name
- NCT04085445
- Testing
- AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter
- Where
- 9 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Coronary Stenosis
Study Comparing the MiStent SES Versus the XIENCE EES Stent
The primary objective of this study is to compare the performance of MISTENT to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease.
- Trial name
- DESSOLVE III (NCT02385279)
- Testing
- MiStent, XIENCE EES
- Where
- 20 sites in France, Germany and 2 more
- Volunteers
- 1,398 people
- Sponsor
- ECRI bv
Peripheral Arterial Disease
BIOLUX P-III BENELUX All-Comers Registry
The purpose of the BIOLUX P-III BENELUX Registry is to further investigate the safety and clinical performance of the Passeo-18 Lux Drug Coated Ballon when used in daily clinical practice for the treatment of isolated…
- Trial name
- NCT03052309
- Testing
- Passeo-18 Lux DCB
- Where
- 9 sites in Belgium, Luxembourg and 1 more
- Volunteers
- 106 people
- Sponsor
- Biotronik AG
Coronary Artery Disease, Drug-eluting Stent
A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)
This is a prospective, multicenter, historical controlled study. The present clinical study will measure non-inferiority of 12 month TLF rate compared to historical control.The selected historical control is the Xience V arm from…
- Trial name
- NCT01808391
- Where
- Japan
- Volunteers
- 1,204 people, healthy volunteers welcome
- Sponsor
- Associations for Establishment of Evidence in Interventions
de Novo, Symptomatic Ischemic Heart Disease
BIOFLOW-SV All Comers Registry
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.
- Conditions
- de Novo, Symptomatic Ischemic Heart Disease, Restenoses, Coronary
- Trial name
- BIOFLOW-SV (NCT03600948)
- Testing
- Orsiro Sirolimus Eluting Coronary Stent System
- Where
- 2 sites in Brazil
- Volunteers
- 261 people
- Sponsor
- Biotronik AG
Silent Myocardial Infarction, Stable Angina
Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII
The purpose of this study is to compare the effectiveness and safety, at 24 months, of the TITAN2 stent to any bare-metal stent (BMS) in Cobalt-Chromium in a population presenting an indication for these stents among 40% of which…
- Conditions
- Silent Myocardial Infarction, Stable Angina, Acute Coronary Syndrome
- Trial name
- EVIDENCE II (NCT01918150)
- Testing
- Titan 2 stents, Cobalt-Chromium Bare Metal Stents
- Where
- 42 sites in France
- Volunteers
- 1,350 people
- Sponsor
- Hexacath, France
Coronary Artery Disease (CAD)
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
After a stent procedure, it is common practice to prescribe anti-platelet medication to prevent the blood from clotting. The main objective of this study is to determine if there is a better medication strategy to prevent blood…
- Trial name
- NCT01813435
- Testing
- Ticagrelor, Acetylsalicylic Acid, Clopidogrel
- Where
- 130 sites in Australia, Austria and 16 more
- Volunteers
- 15,991 people
- Sponsor
- ECRI bv
Coronary Artery Disease
Coroflex ISAR NEO "All Comers" Post Market Clinical Follow-up (PMCF)
The aim of the study is to assess the safety and efficacy of the device to treat coronary de novo and restenotic lesions.
- Trial name
- NCT03809715
- Testing
- Coroflex® ISAR NEO coronary stent system
- Where
- France
- Volunteers
- 3,520 people
- Sponsor
- B. Braun Melsungen AG